Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povorcitinib in Nonsegmental Vitiligo
NCT06113445Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- Nov 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in nonsegmental vitiligo (NSV) comparing Povorcitinib Dose A with Placebo (2 arms). Primary endpoint: Proportion of Participants Achieving a >= 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index at 52 weeks. Started Nov 2023; status: active, not recruiting.
02
Drugs
povorcitinib
03
Conditions
nonsegmental vitiligo (NSV)
Beyond the preview
Go deeper on NCT06113445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06113445.